Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

MenoBrain Brain Health in Menopausal Women

Coordinator
Universitatsklinikum Jena, Germany
Runs
1 September 2025 to 31 August 2029
Status
Running
EU funding
€4.5m
Total cost
—
Partners
20 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227102

What the project is doing

In the project's own words, from its summary on CORDIS.

With the global population of menopausal women projected to reach 1.2 billion by 2030, menopause represents a critical yet understudied period in women's health. Hormonal changes during this transition pose significant risks to brain health, cognitive function, and emotional well-being, while increasing vulnerability to age-related diseases such as Alzheimer's disease. Despite its profound societal relevance, menopause-related brain changes remain poorly understood, with limited biomarkers and evidence-based interventions available.

MenoBrain aims to fill this gap by training a new generation of 15 doctoral candidates to address the pressing challenges of menopause-related brain health. The DCs will work within a multidisciplinary and international network of 18 participants (11 beneficiaries and 7 partners) spanning neuroimaging, neuropsychology, endocrinology, microbiome research and bioinformatics. MenoBrain will employ cutting-edge methods including advanced neuroimaging (MRI, DTI, PET, EEG), host-microbiome modelling, and computational BrainAGE models.

This integrated approach will explore how hormonal changes associated with menopause and interventions such as menopausal hormone therapy impact cognitive health, gut-brain communication, and aging trajectories. The programme combines scientific excellence with a robust training structure to equip MenoBrain doctoral candidates with expertise in interdisciplinary and intersectoral research, advanced technologies, and transferable skills.

By leveraging state-of-the-art infrastructure, MenoBrain will discover biomarkers for early detection of cognitive dysfunction, improve therapeutic strategies, and advance personalized healthcare for menopausal women. MenoBrain not only addresses a critical gap in women's health research, but also aligns with the EU's agenda to promote healthy aging, gender-specific healthcare, and fostering innovative training for the next generation of leaders in science and industry.

Topics

Who is involved

OrganisationCityCountryRole
Universitatsklinikum JenaJenaGermanyCoordinator
Paris-Lodron-Universitat SalzburgSalzburgAustriaParticipant
Christian-Albrechts-Universitaet Zu KielKielGermanyAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Kerstin MinnichWolfratshausenGermanyAssociatedpartner
Medice Arzneimittel Pütter GmbH & Co. KGIserlohnGermanyAssociatedpartner
Synaptikon GmbHBerlinGermanyAssociatedpartner
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Fundacio Barcelonabeta Brain Research CenterBarcelonaSpainParticipant
Universidad Pompeu FabraBarcelonaSpainAssociatedpartner
Finnadvance OyHelsinkiFinlandParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite De LorraineNancy CedexFranceAssociatedpartner
Vilniaus UniversitetasVilniusLithuaniaParticipant
Alzheimer EuropeSenningerbergLuxembourgAssociatedpartner
Bastiaanse Communication B.V.Bosch En DuinNetherlandsAssociatedpartner
Science MattersVlaardingenNetherlandsAssociatedpartner
Universiteit LeidenLeidenNetherlandsParticipant
Diakonhjemmet Sykehus ASOsloNorwayParticipant
Uppsala UniversitetUppsalaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI